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The devil’s advocate editorial on screening HLA to prevent 
severe drug reactions
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Severe cutaneous adverse [drug] reactions (SCAR) are delayed-onset drug hypersensitivity 
reactions that carry significant morbidity and mortality and impose a major economic burden 
on healthcare systems.1,2 2002 heralded a breakthrough in SCAR and pharmacogenomics 
research with the discovery that HLAB*57:01 strongly associated with abacavir-induced 
Drug-Induced Hypersensitivity Syndrome/Drug Rash with Eosinophilia and Systemic 
Symptoms (DIHS/DRESS, a type of SCAR).3 Mallal et al, then published in 2008 beautiful 
evidence that supported screening HIV patients for HLA-B*57:01 prior to initiating abacavir 
treatment to prevent DIHS/DRESS.4 The field has since exploded, with dozens of HLA-drug 
associations identified in the context of specific drug reactions.5,6 Resultingly, an increasing 
number of studies aimed at evaluating the utility of screening HLA to prevent SCAR are 
being performed. A recent systematic review highlighted the association between dapsone-
induced SCAR and HLA-B*13:01.7 In this issue of JAMA Dermatology, Liu et al, 
demonstrated that screening for HLA-B*13:01 prior to initiating dapsone therapy in leprosy 
patients in China prevented DIHS/DRESS, thus supporting a role for HLA screening.8
Is the decision to screen HLA so simple though? This era of personalized medicine has 
witnessed advancements in technologies capable of detailing an individual’s genetics in less 
time and at lower cost. After all, for just $139 (holiday sale) 23andMe will test your DNA to 
determine your “Health” and “Ancestry”! Moreover, if we can prevent an individual from 
developing a potentially devastating case of SJS/TEN or DIHS/DRESS, are we not obligated 
to do so?
The current state of research in this field is not without challenges, limiting data 
interpretation and generalizability. Several factors ranging from technical constraints in HLA 
typing to the epidemiology of ethnicity and disease to healthcare costs are at play.
First, rigorous data supporting the association between one (to a few) specific HLA alleles 
and a culprit drug in the context of a defined drug reaction are necessary. One major obstacle 
in drug reaction research is reporting bias due to (i) the absence of defined clinical 
phenotypes and (ii) uncertainty in identifying the culprit drug. The former is particularly true 
of studies of DIHS/DRESS which lack agreed upon diagnostic criteria and of SJS which 
may be confused clinically with mycoplasma mucositis, erythema multiforme, or bullous 
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fixed drug. Mallal et al’s study demonstrating the utility of HLAB*57:01 screening to 
prevent abacavir-induced DIHS benefited from diagnosis-confirming patch testing of 
abacavir.4 Unfortunately, few drugs are testable by patch or other ex vivo assay, therefore 
necessitating reliance on clinical opinion alone. Second, many studies are either entirely 
retrospective or compare the prospective HLA screened arm to historical controls. This is 
partly secondary to ethical constraints, as administering an at-risk drug to someone 
possessing the predisposing HLA is potentially dangerous.
Moreover, genetic screening requires a laboratory method that is cost effective, reliable (high 
sensitivity, specificity and predictive values), and practical. Multiple laboratory techniques 
are currently used for HLA typing both clinically and in research. Methods vary widely in 
cost, technical difficulty/efficiency, result ambiguity, and sensitivity and specificity.5,9 The 
advent of Next Generation Sequencing has revolutionized the field by improving accuracy 
and resolving ambiguity,10 but it is expensive. The screening method employed can therefore 
impact both pharmacogenomic and cost-effectiveness analyses.
Further complicating matters, not all patients who screen positive for a predisposing HLA 
allele develop a drug reaction despite receiving the at-risk drug, i.e. positive predictive value 
(PPV) of HLA screening is highly variable.11 For example, while HLA-B*57:01 is 
estimated to have a 55% PPV for abacavir-induced DIHS/DRESS, HLA-B*15:02 is 
estimated at only 3% PPV for carbamazepine-induced SJS/TEN.11 Technical limitations 
contribute to this variability, but there are probably additional, less obvious factors. Is it a 
concurrent viral infection overturning peripheral tolerance mechanisms, or is the patient a 
slow metabolizer or have compromised excretion resulting in high drug levels? The 
existence of protective HLA alleles against specific drug reactions has also been suggested.
12
 These are active areas of research with early supportive evidence but are likely only the 
tip of the iceberg. Regardless of underlying reason, if HLA screening has low positive 
predictive value, screening may not be warranted. An interesting nuance is whether the 
benefit of screening HLA for specific drug/drug reaction is dependent on underlying disease. 
Liu et al, contemplated in their article whether their findings of screening to prevent 
dapsone-induced DIHS in leprosy patients is applicable to patients with underlying 
inflammatory conditions responsive to dapsone.8 Given the existence of additional “X” 
factor(s) in determining patient susceptibility to drug reactions, it may be premature to 
assume generalizable.
Additionally, if the prevalence of a specific HLA allele is low amongst a population, the cost 
of screening will grow relative to its benefit. This runs concurrent to a population’s 
heterogeneity. While screening for HLA-B*15:02 is clearly beneficial in Taiwan, where 
~8% population is HLA-B*15:02 positive,13 blindly screening the United States’ population 
for the same HLA allele before starting carbamazepine would be outrageously expensive 
with little yield. To this point, the US Food and Drug administration recommends HLA-
B*15:02 screening prior to initiating carbamazepine treatment in persons of Asian ancestry.
14
 A study in Malaysia similarly concluded that broadly screening patients for HLA-
B*15:02 in their ethnically-diverse population is not cost-effective.15
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The consequences of having the drug reaction must be weighed against the consequences of 
drug avoidance. Most dermatologists are well aware of the potential devastation from 
SCAR. The consequences of drug avoidance may be overlooked. Do efficacious and safe 
alternative therapies exist? Are they affordable? Of course, in the absence of reasonable 
alternative agents, screening could still prove beneficial by alerting the clinician to closely 
monitor the patient or potentially initiate therapy at a lower dose. The JAMA Dermatology 
article by Liu et al, broaches a very intriguing potential consequence of excluding dapsone 
from treatment regimens in HLA-B*13:01 patients with leprosy: drug resistance. The study 
could not assess this owing to the slow growing nature of Mycobacterium leprae (drug 
resistance would not be appreciated for potentially several years).8 What if the at-risk drug 
was used for treating tuberculosis? Or vancomycin-resistant enterococci?
The final challenge is defining and measuring the “benefit” or “utility” of screening. This is 
typically interpreted to mean cost-effectiveness, i.e. weighing cost of treating SCAR relative 
to cost of HLA screening and/or cost of alternative drugs. It may be exceedingly difficult to 
apply cost analyses performed in one society to another given stark differences in healthcare 
systems. Each society will likely need to perform independent cost-effectiveness analysis in 
the context of their healthcare system and in concert with the prevalence of predisposing 
HLA alleles and incidence of SCAR among HLA positive individuals in their respective 
population. Additional commonly used measures include lifetime saved, quality-adjusted 
life years gained and number needed to screen to prevent one case of drug reaction. These 
too are directly influenced by HLA and disease prevalence.
Conclusion:
Currently the FDA and other organizations such as the ACR recommend haplotype 
screening in select populations before starting specific drugs (i.e. abacavir, carbemazepine, 
allopurinol). As technology continues to advance and more HLA-drug associations are 
revealed, it may become cost-effective to preemptively HLA genotype each one of us to 
generate a personalized at-risk drug list. Until then, it seems prudent to rigorously collect, 
analyze and interpret the data in the context of specific populations, with the above caveats 
in mind, to determine the true value of HLA screening.
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